Exact Mass: 487.3635

Exact Mass Matches: 487.3635

Found 113 metabolites which its exact mass value is equals to given mass value 487.3635, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine

3-[(17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine

3-[(10-hydroxydocosa-4,7,11,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine

3-[(11-hydroxydocosa-4,7,9,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine

3-[(13-hydroxydocosa-4,7,10,14,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine

3-[(16-hydroxydocosa-4,7,10,13,17,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine

3-[(20-hydroxydocosa-4,7,10,13,16,18-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine

3-[(4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine

3-[(7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine

3-[(8-hydroxydocosa-4,6,10,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine

3-{[18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoyl]oxy}-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.3298)


(4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine

3-({15-[3-(pent-2-en-1-yl)oxiran-2-yl]pentadeca-4,7,10,13-tetraenoyl}oxy)-4-(trimethylazaniumyl)butanoic acid

C29H45NO5 (487.3298)


(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

SCHEMBL16431315

SCHEMBL16431315

C25H45NO8 (487.3145)


   

Calyciphylline P

Calyciphylline P

C30H49NO4 (487.3661)


   
   

Ambruticin VS 4

Ambruticin VS 4

C29H45NO5 (487.3298)


   

N-tetracosanoylanthranilic acid

N-tetracosanoylanthranilic acid

C31H53NO3 (487.4025)


   

3-(3-methylcrotonyl)cassain

3-(3-methylcrotonyl)cassain

C29H45NO5 (487.3298)


   

ethyl 2-(docosanoylamino)benzoate

ethyl 2-(docosanoylamino)benzoate

C31H53NO3 (487.4025)


   

23-O-Acetyl-12beta-hydroxy-solasodin

23-O-Acetyl-12beta-hydroxy-solasodin

C29H45NO5 (487.3298)


   

Piericidin D4

Piericidin D4

C29H45NO5 (487.3298)


   

Gly Lys Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]hexanamido]-5-carbamimidamidopentanoic acid

C20H41N9O5 (487.323)


   

Gly Lys Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-5-carbamimidamidopentanamido]hexanoic acid

C20H41N9O5 (487.323)


   

Gly Arg Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]hexanamido]hexanoic acid

C20H41N9O5 (487.323)


   

Lys Gly Lys Arg

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}hexanamido]-5-carbamimidamidopentanoic acid

C20H41N9O5 (487.323)


   

Lys Gly Arg Lys

(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}pentanamido]hexanoic acid

C20H41N9O5 (487.323)


   

Lys Lys Gly Arg

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]acetamido}-5-carbamimidamidopentanoic acid

C20H41N9O5 (487.323)


   

Lys Lys Arg Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-5-carbamimidamidopentanamido]acetic acid

C20H41N9O5 (487.323)


   

Lys Arg Gly Lys

(2S)-6-amino-2-{2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]acetamido}hexanoic acid

C20H41N9O5 (487.323)


   

Lys Arg Lys Gly

2-[(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]hexanamido]acetic acid

C20H41N9O5 (487.323)


   

Arg Gly Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}hexanamido]hexanoic acid

C20H41N9O5 (487.323)


   

Arg Lys Gly Lys

(2S)-6-amino-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]acetamido}hexanoic acid

C20H41N9O5 (487.323)


   

Arg Lys Lys Gly

2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]hexanamido]acetic acid

C20H41N9O5 (487.323)


   

(Z)-2-pentacos-16-enamidoethanesulfonic acid

(Z)-2-pentacos-16-enamidoethanesulfonic acid

C27H53NO4S (487.3695)


   

Ethyl N-docosanoylanthranilate

Ethyl N-docosanoylanthranilate

C31H53NO3 (487.4025)


   

Poly(oxy-1,2-ethanediyl), .alpha.-sulfo- .omega.-(dinonylphenoxy)-, ammonium salt

Poly(oxy-1,2-ethanediyl), .alpha.-sulfo- .omega.-(dinonylphenoxy)-, ammonium salt

C26H49NO5S (487.3331)


   

Desacetylrocuronium

Desacetylrocuronium

C30H51N2O3+ (487.3899)


   

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine

C29H45NO5 (487.3298)


   

(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine

(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.3298)


   

(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine

(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.3298)


   

(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine

(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine

C29H45NO5 (487.3298)


   

(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine

(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine

C29H45NO5 (487.3298)


   

(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine

(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine

C29H45NO5 (487.3298)


   

(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine

(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.3298)


   

(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine

(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.3298)


   

(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine

(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.3298)


   

(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine

(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine

C29H45NO5 (487.3298)


   

(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine

(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine

C29H45NO5 (487.3298)


   

(3R,20R)-20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyhenicosanoate

(3R,20R)-20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyhenicosanoate

C27H51O7- (487.3635)


   

(3R)-21-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyhenicosanoate

(3R)-21-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyhenicosanoate

C27H51O7- (487.3635)


   
   
   

HexCer 13:2;2O/6:0

HexCer 13:2;2O/6:0

C25H45NO8 (487.3145)


   

HexCer 15:2;2O/4:0

HexCer 15:2;2O/4:0

C25H45NO8 (487.3145)


   

HexCer 17:2;2O/2:0

HexCer 17:2;2O/2:0

C25H45NO8 (487.3145)


   

HexCer 16:2;2O/3:0

HexCer 16:2;2O/3:0

C25H45NO8 (487.3145)


   

HexCer 14:2;2O/5:0

HexCer 14:2;2O/5:0

C25H45NO8 (487.3145)


   

HexCer 12:2;2O/7:0

HexCer 12:2;2O/7:0

C25H45NO8 (487.3145)


   

(7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxynonan-2-yl)docosa-7,10,13,16,19-pentaenamide

(7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxynonan-2-yl)docosa-7,10,13,16,19-pentaenamide

C31H53NO3 (487.4025)


   

(10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]docosa-10,13,16,19-tetraenamide

(10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]docosa-10,13,16,19-tetraenamide

C31H53NO3 (487.4025)


   

(4Z,7Z,10Z,13Z)-N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

C31H53NO3 (487.4025)


   

(9Z,12Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]heptadeca-9,12-dienamide

(9Z,12Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]heptadeca-9,12-dienamide

C31H53NO3 (487.4025)


   

(6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]octadeca-6,9,12,15-tetraenamide

C31H53NO3 (487.4025)


   

(9Z,12Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]hexadeca-9,12-dienamide

(9Z,12Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]hexadeca-9,12-dienamide

C31H53NO3 (487.4025)


   

(8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]icosa-8,11,14,17-tetraenamide

(8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]icosa-8,11,14,17-tetraenamide

C31H53NO3 (487.4025)


   

(9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]octadeca-9,12,15-trienamide

(9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]octadeca-9,12,15-trienamide

C31H53NO3 (487.4025)


   

(3Z,6Z,9Z,12Z,15Z)-N-(1,3-dihydroxytridecan-2-yl)octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-(1,3-dihydroxytridecan-2-yl)octadeca-3,6,9,12,15-pentaenamide

C31H53NO3 (487.4025)


   

(5Z,8Z,11Z,14Z,17Z)-N-(1,3-dihydroxyundecan-2-yl)icosa-5,8,11,14,17-pentaenamide

(5Z,8Z,11Z,14Z,17Z)-N-(1,3-dihydroxyundecan-2-yl)icosa-5,8,11,14,17-pentaenamide

C31H53NO3 (487.4025)


   

(7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]hexadeca-7,10,13-trienamide

(7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]hexadeca-7,10,13-trienamide

C31H53NO3 (487.4025)


   

(4E,8E)-3-hydroxy-2-(undecanoylamino)pentadeca-4,8-diene-1-sulfonic acid

(4E,8E)-3-hydroxy-2-(undecanoylamino)pentadeca-4,8-diene-1-sulfonic acid

C26H49NO5S (487.3331)


   

(4E,8E)-3-hydroxy-2-(tridecanoylamino)trideca-4,8-diene-1-sulfonic acid

(4E,8E)-3-hydroxy-2-(tridecanoylamino)trideca-4,8-diene-1-sulfonic acid

C26H49NO5S (487.3331)


   

(4E,8E)-3-hydroxy-2-(tetradecanoylamino)dodeca-4,8-diene-1-sulfonic acid

(4E,8E)-3-hydroxy-2-(tetradecanoylamino)dodeca-4,8-diene-1-sulfonic acid

C26H49NO5S (487.3331)


   

(E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]undec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]undec-4-ene-1-sulfonic acid

C26H49NO5S (487.3331)


   

(E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid

(E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid

C26H49NO5S (487.3331)


   

(4E,8E)-2-(decanoylamino)-3-hydroxyhexadeca-4,8-diene-1-sulfonic acid

(4E,8E)-2-(decanoylamino)-3-hydroxyhexadeca-4,8-diene-1-sulfonic acid

C26H49NO5S (487.3331)


   

(4E,8E)-2-(dodecanoylamino)-3-hydroxytetradeca-4,8-diene-1-sulfonic acid

(4E,8E)-2-(dodecanoylamino)-3-hydroxytetradeca-4,8-diene-1-sulfonic acid

C26H49NO5S (487.3331)


   

(E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]dodec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]dodec-4-ene-1-sulfonic acid

C26H49NO5S (487.3331)


   

2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxydecane-1-sulfonic acid

2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxydecane-1-sulfonic acid

C26H49NO5S (487.3331)


   

(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tridec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tridec-4-ene-1-sulfonic acid

C26H49NO5S (487.3331)


   
   

4-(3-Heptanoyloxy-2-nonanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Heptanoyloxy-2-nonanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C26H49NO7 (487.3509)


   

4-[2,3-Di(octanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate

4-[2,3-Di(octanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate

C26H49NO7 (487.3509)


   

4-(3-Propanoyloxy-2-tridecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Propanoyloxy-2-tridecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C26H49NO7 (487.3509)


   

4-(3-Butanoyloxy-2-dodecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Butanoyloxy-2-dodecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C26H49NO7 (487.3509)


   

4-(3-Pentanoyloxy-2-undecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Pentanoyloxy-2-undecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C26H49NO7 (487.3509)


   

4-(3-Acetyloxy-2-tetradecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Acetyloxy-2-tetradecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C26H49NO7 (487.3509)


   

4-(2-Decanoyloxy-3-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(2-Decanoyloxy-3-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C26H49NO7 (487.3509)


   

bhos#38(1-)

bhos#38(1-)

C27H51O7 (487.3635)


Conjugate base of bhos#38

   

bhas#38(1-)

bhas#38(1-)

C27H51O7 (487.3635)


Conjugate base of bhas#38

   

NA-Cit 22:5(7Z,10Z,13Z,16Z,19Z)

NA-Cit 22:5(7Z,10Z,13Z,16Z,19Z)

C28H45N3O4 (487.341)


   

NA-DOPA 20:2(11Z,14Z)

NA-DOPA 20:2(11Z,14Z)

C29H45NO5 (487.3298)


   
   
   
   
   
   

ST 27:3;O3;Gly

ST 27:3;O3;Gly

C29H45NO5 (487.3298)


   

ST 28:2;O2;Gly

ST 28:2;O2;Gly

C30H49NO4 (487.3661)


   

[6-(2-{2-[5-(6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl)-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl}ethenyl)-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid

[6-(2-{2-[5-(6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl)-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl}ethenyl)-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid

C29H45NO5 (487.3298)


   

(1s,4s,10s,12s)-12-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione

(1s,4s,10s,12s)-12-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione

C31H41N3O2 (487.3199)


   

23-o-acetyl-12β-hydroxysolasodine

23-O-acetyl-12β-hydroxysolasodine

C29H45NO5 (487.3298)


{"Ingredient_id": "HBIN004134","Ingredient_name": "23-o-acetyl-12\u03b2-hydroxysolasodine","Alias": "23-O-acetyl-12\u03b2-hydroxysolasodine","Ingredient_formula": "C29H45NO5","Ingredient_Smile": "C29H45NO5","Ingredient_weight": "487.67","OB_score": "12.16578116","CAS_id": "117803-97-1","SymMap_id": "SMIT08805","TCMID_id": "37260","TCMSP_id": "MOL007352","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

2-aminobenzoic acid,9ci; n-docosanoyl,et ester

NA

C31H53NO3 (487.4025)


{"Ingredient_id": "HBIN005318","Ingredient_name": "2-aminobenzoic acid,9ci; n-docosanoyl,et ester","Alias": "NA","Ingredient_formula": "C31H53NO3","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8700","PubChem_id": "NA","DrugBank_id": "NA"}

   

n-{3-[(5z,8z,11z)-n-(5-carbamimidamidopentyl)tetradeca-5,8,11-trienamido]propyl}-3-methylbut-2-enimidic acid

n-{3-[(5z,8z,11z)-n-(5-carbamimidamidopentyl)tetradeca-5,8,11-trienamido]propyl}-3-methylbut-2-enimidic acid

C28H49N5O2 (487.3886)


   

3-(acetyloxy)-4-(dodecanoyloxy)-n-(2-hydroxy-4-methoxy-4-oxobutyl)-2-methylpentanimidic acid

3-(acetyloxy)-4-(dodecanoyloxy)-n-(2-hydroxy-4-methoxy-4-oxobutyl)-2-methylpentanimidic acid

C25H45NO8 (487.3145)


   

n-[2-(ethoxycarbonyl)phenyl]docosanimidic acid

n-[2-(ethoxycarbonyl)phenyl]docosanimidic acid

C31H53NO3 (487.4025)


   

(1s,2r,3s,7r,11s,13s,14r)-2-[(3s)-3-[(1r,4s,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-hydroxypropyl]-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-11-ol

(1s,2r,3s,7r,11s,13s,14r)-2-[(3s)-3-[(1r,4s,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-hydroxypropyl]-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-11-ol

C30H49NO4 (487.3661)


   

(1s,2r,3s,7r,10s,11s,13s,14r)-2-[(3s)-3-[(1r,4s,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-hydroxypropyl]-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-11-ol

(1s,2r,3s,7r,10s,11s,13s,14r)-2-[(3s)-3-[(1r,4s,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-hydroxypropyl]-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-11-ol

C30H49NO4 (487.3661)


   

[(2s,4s,5r,6s)-6-[(1e)-2-[(1s,2s,3r)-2-[(1e,3r,4e)-5-[(2r,6r)-6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl]-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl]ethenyl]-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid

[(2s,4s,5r,6s)-6-[(1e)-2-[(1s,2s,3r)-2-[(1e,3r,4e)-5-[(2r,6r)-6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl]-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl]ethenyl]-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid

C29H45NO5 (487.3298)


   

2-(3-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-hydroxypropyl)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-11-ol

2-(3-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-hydroxypropyl)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-11-ol

C30H49NO4 (487.3661)


   

n-{3-[n-(5-carbamimidamidopentyl)tetradeca-5,8,11-trienamido]propyl}-3-methylbut-2-enimidic acid

n-{3-[n-(5-carbamimidamidopentyl)tetradeca-5,8,11-trienamido]propyl}-3-methylbut-2-enimidic acid

C28H49N5O2 (487.3886)


   

3-(acetyloxy)-4-(dodecanoyloxy)-n-[(2r)-2-hydroxy-4-methoxy-4-oxobutyl]-2-methylpentanimidic acid

3-(acetyloxy)-4-(dodecanoyloxy)-n-[(2r)-2-hydroxy-4-methoxy-4-oxobutyl]-2-methylpentanimidic acid

C25H45NO8 (487.3145)